EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker

Bright C Uzuegbunam, Junhao Li, Wojciech Paslawski iD, Wolfgang Weber, Per Svenningsson iD, Hans Ågren iD, Behrooz Hooshyar Yousefi iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242216445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Bright C Uzuegbunam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Technical University of Munich, 81675 Munich, Germany. Hauptthemen laut MEDLINE: Synucleinopathies, Neurodegenerative Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parkinsonfonds Deutschland, the Michael J. Fox Foundation, the Rainwater Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The α-synucleinopathies are a group of neurodegenerative diseases characterized by the deposition of α-synuclein aggregates (α-syn) in the brain. Currently, there is no suitable tracer to enable a definitive early diagnosis of these diseases. We reported candidates based on 4,4′-disarylbisthiazole (DABTA) scaffold with a high affinity towards α-syn and excellent selectivity over Aβ and tau fibrils. Based on prior in silico studies, a focused library of 23 halogen-containing and O-methylated DABTAs was prepared. The DABTAs were synthesized via a modified two-step Hantzsch thiazole synthesis, characterized, and used in competitive binding assays against [3H]PiB and [3H]DCVJ. The DABTAs were obtained with an overall chemical yield of 15–71%, and showed a calculated lipophilicity of 2.5–5.7. The ligands demonstrated an excellent affinity to α-syn with both [3H]PiB and [3H]DCVJ: Ki 0.1–4.9 nM and up to 20–3900-fold selectivity over Aβ and tau fibrils. It could be concluded that in silico simulation is useful for the rational design of a new generation of DABTAs. Further investigation of the leads in the next step is encouraged: radiolabeling of the ligands with radioisotopes such as fluorine-18 or carbon-11 for in vivo, ex vivo, and translational research and for further in vitro experiments on human-derived protein aggregates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynucleinopathiesNeurodegenerative DiseasesHumansalpha-SynucleinProtein AggregatesLigandsBiomarkers

Stichwörter der Autor:innen

4,4′-diarylbisthiazoleHantzsch thiazole synthesisO-fluoroPEGylationO-fluoroethylationO-methylationbinding affinitylipophilicityα-synuclein aggregates

Substanzen

alpha-SynucleinProtein AggregatesLigandsBiomarkers

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Technical University of Munich, 81675 Munich, Germany.
  • Department of Physics and Astronomy, Uppsala University, 751 20 Uppsala, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Department of Nuclear Medicine, Philipps University of Marburg, 35043 Marburg, Germany.

ORCID-Profile: Wojciech Paslawski, Per Svenningsson, Hans Ågren, Behrooz Hooshyar Yousefi

Förderung

  • Parkinsonfonds Deutschland
  • the Michael J. Fox Foundation
  • the Rainwater Charitable Foundation
  • the National Academic Infrastructure for Super-computing in Sweden (NAISS) at the National Supercomputer Centre at Linköping University (Sweden)
  • the Swedish Research Council

Zitieren

APA

Uzuegbunam, B. C., Li, J., Paslawski, W., Weber, W., Svenningsson, P., Ågren, H., & Hooshyar Yousefi, B. (2023). In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216445

Vancouver

Uzuegbunam BC, Li J, Paslawski W, Weber W, Svenningsson P, Ågren H, et al. In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216445

BibTeX
@article{Uzuegbunam2023,
  author = {Uzuegbunam, Bright C and Li, Junhao and Paslawski, Wojciech and Weber, Wolfgang and Svenningsson, Per and Ågren, Hans and Hooshyar Yousefi, Behrooz},
  title = {In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242216445}
}
Kostenlos starten →